

The impact of diagnostic methods on the diagnosis of *Clostridium difficile* infection



Esihle Nomlomo

Student number 1316776

enomlomo@gmail.com

083 317 3307

The impact of diagnostic methods on the diagnosis of *Clostridium difficile* infection

Esihle Nomlomo¹ MBChB (UCT) and Trusha Nana MBBCh (Wits), DTM&H, FCPath (Micro)¹

¹ Microbiology Laboratory, Charlotte Maxeke Johannesburg Academic Hospital, Department of Clinical Microbiology and Infectious Diseases, National Health Laboratory Service and University of the Witwatersrand, Johannesburg

Abstract

Background: *Clostridium difficile* is a common cause of healthcare-associated diarrhoea. Laboratory testing for *C. difficile* infection (CDI) remains an area of confusion as there is not a single accepted reference standard or a single best test.

Aim: To analyse the impact of different diagnostic methods on reported CDI rates. In addition, CDI incidence rates at Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) were determined.

Method: Results of stool samples submitted for *C. difficile* testing at CMJAH from 1 January 2014 to 31 August 2017 were reviewed. From January 2014 to July 2016, samples were tested by polymerase chain reaction (PCR) or toxin immunoassay, and from August 2016 to August 2017 algorithm-based testing (glutamate dehydrogenase and toxin immunoassay followed by PCR) was performed.

Results: A total of 4829 samples were submitted. For the first period, toxin immunoassay and PCR showed a positivity rate of 11.4% and 21.1%, respectively, with an overall positivity rate of 18.7% (95% CI: 15.6 – 21.9). For the second period, the positivity rate was 15.9% (95% CI: 11.3 – 17.7). This rate included samples that were GDH positive and either showed toxin production or had a positive Xpert® result. CDI incidence for the two periods was different, with an incidence rate of 8.8 and 6.1 per 10 000 patient-days for the first and second periods, respectively.

Conclusion: The choice of laboratory testing method has a major impact on the diagnosis of CDI, and therefore on the reported rates of CDI. Standardisation of laboratory testing and incidence rate reporting is required in order to obtain robust and reliable data.

Background

Clostridium difficile is a common cause of healthcare-associated diarrhoea. The clinical outcome depends on host factors and the virulence of the toxin-producing strain. This organism causes disease that ranges in severity, from asymptomatic colonisation to severe diarrhoea, pseudomembranous colitis, toxic megacolon, colonic perforation and death [1, 2, 3]. The principal risk factor for *C. difficile* infection (CDI) is prior antibiotic therapy [4].

Results of a systematic review assessing the epidemiology of CDI in Low and Middle Human Development Index (LMHDI) countries show that there is a paucity of published literature describing the epidemiology and burden of CDI [2]. Rajabally et al. highlight that data relating to the burden of *C. difficile*-associated disease (CDAD) in southern Africa is limited. The study conducted by this group emphasises that the magnitude of CDI burden in South African hospitals is not known [1, 3].

Freeman et al. notes the two key issues that hinder the understanding of the epidemiology of CDI. Firstly, there is poor recognition and documentation of CDAD [5]. The second obstacle is the many different approaches to the laboratory diagnosis of CDI. This is a dilemma also encountered in South Africa [5]. There are numerous targets and combinations of targets that can be used to detect *C. difficile* (cell cytotoxicity assays (CCA), toxigenic culture, glutamate dehydrogenase (GDH), toxins through enzyme immunoassay (EIA) and toxin genes through polymerase chain reaction (PCR). Researchers in the United Kingdom have noted a variation in the reference standards for CDI diagnosis. This gives rise to differences in the assessment of the diagnostic performance of assays and contributes to uncertainty in diagnosing CDI [6,7]. Hence, it is likely that the measured incidence of infection will vary according to the laboratory diagnostic method used [5,6,7].

PCR-based testing is unable to differentiate between infection and colonisation. As a result, reliance on it as a stand-alone test may result in over-diagnosis of CDI [3]. The low sensitivity of toxin EIAs also makes these unsuitable as stand-alone tests [3, 6]. For this reason, an algorithm that includes a sensitive assay (GDH or PCR) followed by specific assay (toxin detection) may provide more accurate results [8]. The Society for Healthcare Epidemiology of America (SHEA), the Infectious Disease Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) all recommend the use of multi-step algorithms for the diagnosis of CDI [8, 9]. These algorithms allow reliable exclusion of CDI without additional tests if the GDH screen or PCR is negative [8]. This reduces the turnaround time significantly, while providing accurate results [8, 9].

Prior to July 2016, the Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) Microbiology Laboratory used stand-alone PCR and stand-alone toxin EIA for CDI diagnosis. Currently, a two-step algorithm for CDI diagnosis is used. A rapid EIA for GDH and toxin A/B is the initial test, followed by PCR on the subset of samples that are GDH positive and toxin negative. The aim of this study is to analyse the results yielded by the diagnostic methods used in the two periods and their impact on the reported rates of CDI. The secondary objective is to estimate the incidence of CDI in the overall patient population at CMJAH, as well as specific at-risk patient populations such as critical care, oncology, surgical and gastroenterology patients.

Methods

Design and setting

This is a retrospective descriptive study. CMJAH is a 1088-bed tertiary hospital in Johannesburg. Results of stool samples submitted for *C. difficile* testing at CMJAH from 1 January 2014 to 31 August 2017 were reviewed. Laboratory data was requested from the National Health Laboratory Service (NHLS) and Corporate Data Warehouse (CDW).

Microbiological testing

Formed stools were rejected by the laboratory. Samples with delayed transport to the laboratory (more than 2 hours post collection) were not rejected. During the period January 2014 to July 2016, laboratory testing for CDI was performed using two test methods. The test method used in each case was determined by when the sample was submitted. Samples that were collected during the regular working hours of 07:00 - 17:00 were analysed using PCR (Xpert® *C. difficile* by Cepheid, Sunnyvale, USA). The test method used after hours, from 17:00 - 07:00 and during weekends, was the EIA Immuno-Card® Toxin A & B assay (Meridian Bioscience, Cincinnati, OH).

Samples that tested either PCR positive with Xpert® *C. difficile* or toxin positive with the Immuno-Card® Toxin A & B assay were interpreted as positive for analysis purposes.

From 1 August 2016, a two-step algorithm was used for laboratory diagnosis of CDI. The C. Diff Quik Chek Complete® (TechLab, Blacksburg, VA) detects GDH as a screen for the presence of *C. difficile*. This assay also detects the presence of toxin A and B. A positive result for both the GDH and toxin indicates *C. difficile* disease. In contrast, a positive result for only the GDH component may indicate the presence of a non-toxin producing strain. For samples that test GDH positive, toxin negative, reflex PCR (Xpert® *C. difficile* by Cepheid) testing was performed to detect the presence of toxin-encoding gene.

Data for epidemiology review was sort according to the current reporting and interpretation standard operation procedure at the NHLS ^[10].

1. GDH negative and toxin negative: *Clostridium difficile* not detected
2. GDH positive and toxin positive: Toxin producing *Clostridium difficile* detected
3. GDH negative and toxin positive: Indeterminate results, repeat specimen to be submitted to the laboratory
4. GDH positive and toxin negative: *Clostridium difficile* antigen detected, toxin not detected. Toxin encoding gene detected/ not detected by PCR.

Samples that tested GDH positive and toxin positive were referred to as “true positives” for analysis purposes. True positives together with samples that tested GDH positive, toxin negative and PCR positive were referred to as “all positives”. Samples with indeterminate results were excluded from the analysis.

Repeat samples within a 2-week period were excluded from the analysis.

Patient days data for calculation of incidence rates was obtained from the hospital. The combined PCR positive and EIA positive results were used for calculation of the incidence

rates for the January 2014-July 2016 period and “all positives” for the August 2016-August 2017 period.

Statistical analysis

The positivity rate for each diagnostic method was calculated by dividing the positive CDI results by the total number of samples over the relevant periods (January 2014-July 2016 and August 2016-August 2017).

The paediatric and adult patient-days for the relevant period were used as the denominator for the incidence of CDI rate calculations.

95% confidence intervals (CI) were determined for the incidence rates for the two periods.

Stata statistical software version 14 was used for the analysis.

The study was approved by the University of Witwatersrand Human Research Ethics Committee (HREC) no. M170941.

Results

Table 1: Impact of different laboratory testing strategies

Table 1.1 Depicting testing period January 2014 – July 2016

Total number of Xpert® positive	Total number of samples	Positivity rate (95% confidence interval (CI))
554	2622	21.13% (19.52 – 23.10)
Total number of Meridian Immuno-Card® positives	Total number of samples	Positivity rate (95% CI)
96	841	11.41% (10.78 – 12.21)
Total positive samples	Total number of samples	Positivity rate (95% CI)
650	3463	18.77% (15.6 – 21.9)

Table 1.2 Depicting testing period August 2016 – August 2017

Total number of C. Diff Quik Chek Complete® (GDH positive – toxin positive)	Total number of samples	Positivity rate (95% CI)
118	1366	8.64% (7.94 – 9.23)
Total number of GDH positive, toxin negative and Xpert® positive	Total number of samples	Positivity rate (95% CI)
99	1366	7.25% (6.91 – 7.94)
Total positive samples	Total number of samples	Positivity rate (95% CI)
217	1366	15.89% (11.3 – 17.7)

A total of 650 samples tested positive from the 3463 samples collected from January 2014 until July 2016 (EIA and PCR method). The overall positivity rate was 18.7% (95% CI: 15.6 – 21.9) (Table 1.1).

A total of 1366 samples were submitted during the second test period and 217 were positive, with a positivity rate of 15.9% (95% CI: 11.3 – 17.7). This rate included all the samples that were GDH positive and either showed toxin production (54%) or had a positive Xpert® result (46%) (Table 1.2.).

Table 2: Incidence density of *C. difficile*

Test period	Total positive samples	Total patient days	Incidence rate per 10 000 patient-days 95% CI
Jan 2014 - July 2016	650	735240	8.84 (8.17 – 9.55)
Aug 2016 – Aug 2017	217	357871	6.06 (5.28 – 6.92)




Figure 3: Unit specific incidence density

For the study period of August 2016 – August 2017, the multidisciplinary ICU had the highest incidence of CDI at 46.1 per 10 000 patient-days. The second-highest incidence rate was seen in the trauma ICU, followed by the infectious disease unit with rates of 29.1 and 27 per 10 000 patient-days respectively (Figure 3). For many of the units a large proportion of the positive results were toxin negative, Xpert® positive.

Paediatric medical and paediatric surgical units had an overall low incidence rate of 2.1 and 1 per 10 000 patient-days (Figure 3).

Discussion

The different laboratory testing strategies utilised by the CMJAH laboratory had a substantial impact on the reported CDI rates. In the first study period, stand-alone PCR-based testing yielded almost double the number of positive results when compared to stand-alone toxin EIA testing. Similarly, in the second study period, reflex PCR-based testing of GDH-positive, toxin-negative samples almost doubled the number of positive results when compared to GDH and toxin EIA testing alone. The difference in the laboratory testing methods and stand-alone PCR testing specifically, for a large proportion of the samples in the first study period, probably contributed considerably to the higher CDI incidence rate for the first study period. The overall CDI incidence rate at CMJAH is comparable to endemic rates reported from other regions ^[17]. Some hospital units had high CDI rates. However, a proportion of the positive results may reflect colonisation rather than CDAD.

Laboratory testing for CDI is a rapidly-changing field. It is also an area of confusion because there is not a single accepted reference standard or a single best test ^[11]. The usefulness of a CDI diagnostic test is judged on its sensitivity, specificity, turnaround time (TAT), cost and availability ^[11]. Toxigenic culture and CCA are regarded as the reference tests for the laboratory diagnosis of CDI ^[6, 8]. However, these assays are not widely used due to their long turnaround times and technical requirements ^[12].

These assays also pose a challenge in clinical interpretation and diagnostic method validations, as they have different targets and are not directly comparable ^[6, 8]. Planche et al., in a study that compares results of toxigenic culture and CCA to clinical outcomes, report that the two reference tests provide different data ^[6]. This study shows that a positive CCA result correlates with CDAD, whereas a positive toxigenic culture (with negative CCA) is more likely to indicate asymptomatic *C. difficile* colonisation ^[6]. In keeping with these findings, the ESCMID review of CDI diagnostics concludes that when toxin is not detected from a sample but toxigenic culture is positive, further evaluation is required to distinguish asymptomatic colonisation from true CDI ^[8].

During the first study period, PCR-based testing (Xpert®) yielded a higher positivity rate compared to toxin EIA testing. PCR-based testing has been shown to be rapid, but is criticised for showing suboptimal specificity for CDI diagnosis. ^[11, 12] Increased CDI rates associated with PCR-based testing, compared to toxin detection-based diagnosis, have been reported in other studies ^[6, 12]. In a study assessing the impact of diagnostic assay type on CDI and the associated complication rates, Longtin et al. find that PCR alone is associated with more than a 50% increase in CDI incidence when compared with algorithm-based testing ^[12]. PCR-based testing like toxigenic culture can have a low specificity, and hence a low positive predictive value (PPV), for CDI diagnosis, and generally should not be used alone, but instead as part of a multistep algorithm ^[6, 8, 9]. However, in high prevalence settings or in patients with high pre-test probability of CDI, PCR will have a more favourable PPV for CDI ^[6, 13]. The 2017 IDSA CDI guidelines support the use of stand-alone PCR in patients with a high pre-test probability of CDI ^[9].

Studies have shown that toxin EIA tests are less sensitive and results are variable due to toxin degradation associated with delayed sample testing ^[3]. Delayed processing may have contributed to the lower positive rate in the current study. In a study from the Western Cape, South Africa, researchers attributed a lower CDI burden to strain diversity and low levels of toxin production ^[3]. In this study, the positivity rate of Xpert® (21.13%) was almost double

that of EIA (11.41%). Although toxin EIAs are rapid, widely available and inexpensive, they have poor sensitivity and are no longer recommended as stand-alone tests ^[11].

In view of the increasing evidence that stand-alone assays for CDI diagnosis are suboptimal, the laboratory at CMJAH implemented a two-step algorithm in August 2016. Use of the two-step algorithm may have decreased the number of false positive results and allowed for stratification of patients into those without CDI, those with CDI and potential carriers for *C. difficile* ^[6, 8, 9].

The majority of clinical laboratories do not use reference methods in multistep algorithms ^[11]; however, the use of diagnostic methods that have been validated using the reference methods is common ^[8]. Avila et al. showed that the combined sensitivity of assays such as C. Diff Quik Chek® (GDH and toxin detection in a single assay), range between 80-100%, and the specificity between 87-100% ^[11]. However, in such assays the sensitivity of the toxin component is not certain and hence, there is a role for PCR-based testing of GDH positive, toxin negative samples ^[8, 9].

The positivity rate of samples that were tested by a second test (Xpert®) in the two-step algorithm was 7.25%. The clinical relevance of samples that are GDH positive, toxin negative and PCR positive is still not clear. The patient may have CDI with low toxin levels that are not detectable with the EIA used. Alternatively, the patient may simply be colonised with toxigenic *C. difficile* ^[6, 8]. The decision as to whether to treat these patients should be based on the pre-test probability of CDI and clinical evaluation of the patients. Colonised patients do, however, play a role in transmission of infection and implementation of contact precautions is indicated ^[8, 9].

It is difficult to interpret the incidence data from the first study period as the testing methodology used was not uniform. The majority of CDI cases were identified by PCR and this may have resulted in a falsely elevated rate. Almost half the positive results in the second study period were toxin negative, Xpert® positive; hence the true CDI incidence for this period may be lower than the reported 6.1 cases per 10 000 patient days.

The incidence density of *C. difficile* was lower in the second study period compared to the first period. The testing rate in the two study periods differed (data not shown) and this may have had some impact on the incidence rates. However, CDI cases were defined using ESCMID and IDSA recommended algorithm-based testing during the second period, thus the data is more robust than that of the first study period ^[4]. The difference in the incidence between the study periods is probably largely due to the move to a testing methodology (algorithm-based testing) that has been shown to have an increased accuracy for CDI diagnosis ^[12, 16]. Importantly, these results illustrate the need for uniform laboratory testing methodologies and surveillance definitions to promote reliable data generation, as well as improved interpretation and comparison of CDI incidence rates.

A CDI incidence rate of 5.3 per 10 000 patient days was found in a meta-analysis from Asia, which was similar to that reported in Europe and North America and indicated by the results of this study ^[17]. Over the last few decades there have been reports of widespread increases in the incidence, severity and mortality associated with CDI. However, there is a paucity of South African data. Rajabally et al. found that the incidence of CDI in their South African tertiary institution was much lower than that reported in the West ^[1]. However, limitations of

their study include that standalone toxin EIA testing was performed. The findings of the current study provide some of the much-needed local data ^[1, 2].

Analysis of the incidence density of specific units showed the multidisciplinary ICU to have highest incidence rate. Critically-ill patients are at increased risk for CDI due to multifactorial causes. Risk factors include the use of broad spectrum antimicrobials, gastric acid suppression, advanced age, prolonged hospitalization, enteral feeds, chronic kidney disease and deficient immune status that are associated with development CDI ^[1, 3, 13, 20, 21, 22].

Other units showing particularly high CDI incidence rates were the trauma, infectious diseases and gastrointestinal surgical units. Elevated incidence rates were also present in the medical oncology, gastroenterology/haematology, renal transplant and renal/nuclear medicine units. Each of these patient populations have well-recognised risk factors for CDI.

Paediatric units showed an overall low incidence density. *C. difficile* is generally non-pathogenic in infants ^[24]. In children aged 1-3 years CDI may occur but other aetiologies, especially viral, are more common ^[24]. In older children, increasing CDI rates have been documented in some settings ^[24].

Strengths of this study are that the results for a large number of samples were available for analysis, reducing potential bias towards any test method. During the first study period all the samples were not tested by both PCR and toxin EIA however, sample allocation to a particular method was based only on the time of sample receipt in the laboratory. In the second study period, the testing algorithm used is in alignment with international guidelines and recommendations. Similarly, the calculation of CDI incidence rates was based on recognised surveillance definitions.

This study is limited by its retrospective design with potential to introduce bias. Our practice was restricted to the use of specific commercially available kits in order to perform EIA and PCR testing. The testing rate in the two study periods was not uniform and thus definitive conclusions regarding the difference in the incidence rates cannot be made. The clinical significance of the subgroup GDH positive, toxin negative and PCR positive results require further elucidation. It is difficult to assess the magnitude of the overestimation of CDI rates related to PCR testing in both study periods. This study was conducted at a single centre; therefore, caution should be exercised in extrapolating this data to other settings.

This study has demonstrated that the overall reported CDI incidence rate decreased with the introduction of a two-step algorithm for laboratory diagnosis of CDI. Standardisation is required of laboratory testing methodology and CDI incidence rate reporting, in order to yield robust data. Laboratories must incorporate detection of free toxin in their testing algorithms and clearly indicate on reports whether free toxin or toxigenic *C. difficile* has been detected. Clinicians must be cognizant of the difference in the implications of these two results.

Conclusion

C. difficile is a major cause of healthcare-associated diarrhoea. Laboratory diagnostics are important to differentiate CDI from other causes of diarrhoea and to establish the presence of infection versus colonisation. The choice of laboratory testing method(s) has a major impact on the diagnosis of CDI, and hence on the reported rates of CDI.

Acknowledgement

I would like to express my sincere appreciation to Dr. Trusha Nana, Clinical Microbiology and Infectious Disease Pathologist, for her unwavering support, encouragement and mentorship. It was a great honour to work under her supervision.

Funding

None

Conflict of interest

None

References

1. Rajabally N, M Pentecost, Pretorius G, Whitelaw A, Mendelson M and Watermeyer G. The *Clostridium difficile* problem: A South African tertiary institutions prospective perspective. SAMJ: South African Medical Journal. 2013 Jan; 103(3):168-172. <http://doi:10.7196/samj.6012>
2. Ferrester JD, Cai LZ, Mbanje C, Rinderkhencht TN and Wren SM. *Clostridium difficile* infection in Low and Middle Human Development Index Countries: A systematic review. A European Journal of Tropical Medicine & International Health. 2017 Aug. <http://doi:10.1111/tmi.12937>
3. Rajabally N, Kullin B, Ebrahim K, Brock T, Weintraub A, Whitelaw A, Bamford C, Watermeyer G, Thomson S, Abratt VR and Reid SJ. A comparison of *Clostridium difficile* diagnostic method for identification of local strains in a South African centre. Journal of Microbiology. 2016 April; 65 (4):320-327. <https://doi:10.1099/jmm.0.000231>
4. Krutova M, Kinross P, Barbut F, Hajud A, Wilcox MH and Kuijper EJ. How to: Surveillance of *Clostridium difficile* infections. Clinical Microbiology and Infection. 2018 May; 24 (5): 469 – 475. <http://doi.org/10.1016/j.cmi.2017.12.008>
5. Freeman J, Bauer MP, Baines SD, Corver J, Fawley WN, Goorhuis B, Kuijper EJ and Wilcox MH. The changing Epidemiology of *Clostridium difficile* Infections. Clinical Microbiology Reviews. 2010 July; 23(3):529-549. <http://doi:10.1128/CMR.00082-09>
6. Planche TD, Davies KA, Coen PG, Finney JM, Monahan IM, Morris KA, O'Connor L, Oakley SJ, Pope CF, Wren MW, Shetty NP, Crook DW and Wilcox MH. Difference in outcome according to *Clostridium difficile* testing methods: a prospective multicenter diagnostic validation study of *C. difficile* infection. Lancet Infectious Diseases. 2013 Sept; 13 (11):936-945. [http://doi:10.1016/S1473-3099\(13\)70200-7](http://doi:10.1016/S1473-3099(13)70200-7)
7. Planche T, Aghaizu A, Holliman R, Riley P, Poloniecki J, Breathnach A and Krishna S. Diagnosis of *Clostridium difficile* infection by toxin detection kits: a systematic review. Lancet Infectious Diseases. 2008 Dec; 8 (12):777-84. [http://doi:10.1016/S1473-3099\(08\)70233-0](http://doi:10.1016/S1473-3099(08)70233-0)
8. Crobach MJT, Planche T, Eckert C, Barbut F, Terveer, Dekker OM, Wilcox MH and Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for *Clostridium difficile* infection. Clinical Microbiology and Infection. 2016 Aug, 22 Supple 4: S63-S81. <http://doi:10.1016/j.cmi.2016.03.010>
9. McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, Gould CV, Loo V, Sammons JS, Sandora TJ and Wilcox MH. Clinical Practice Guidelines for *Clostridium difficile* Infection in Adults and Children: 2017 Update by Infectious Disease of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clinical Infectious Diseases. 2018 March; 66(7):987-94. <http://doi:10.1093/cid/cix1085>

10. National Health Laboratory Services, Standard Operating Procedure document. Q-pulse5/docs/active/MIC 1963v1
11. Avila MB, Avila NP and Dupont AW. Recent advances in the diagnosis and treatment of *Clostridium difficile* infection. FI000Research. 2016 Feb; 5(16):1-5. <http://doi:10.12688/fi000research.7109.1>
12. Longtin Y, Trottier S, Brochu G, Paquet-Bolduc B, Garenc C, Loungnarath V, Beaulieu C, Goulet D and Longtin J. Impact of the Type of Diagnostic Assay on *Clostridium difficile* Infection and Complication Rate in a Mandatory Reporting Program. Clinical Infectious Diseases. 2013 Jan; 59(1):67-73. <http://doi:10.1093/cid/cis840>
13. Deshpande A, Pasupuleti V, Rolston DDK, Jain A, Deshpande N, Pant Chaitanya and Hernandez AV. Diagnostic accuracy of real-time polymerase chain reaction in detection of *Clostridium difficile* in stool samples of patients with suspected *Clostridium difficile* infection: A Meta-Analysis. Clinical Infectious Disease. 2011 Oct; 53(7): 81-90. <http://doi:10.1093/cid/cir505>
14. Polage CR, Solnick JV and Cohen SH. Nosocomial Diarrhoea: Evaluation and Treatment of Causes Other Than *Clostridium difficile*. Clinical Infectious Diseases. 2012 Oct; 55(7):982-9. <http://doi:10.1093/cid/cis551>
15. Brecher SM, Novak-Weekley SM and Nagy E. Laboratory Diagnosis of *Clostridium difficile* Infections: There Is Light at the End of the Colon. Clinical Infectious Diseases. 2013 Oct; 57(8):1175-81. <http://doi:10.1093/cid/cit424>
16. Yoldas O, Altindis M, Cufali D, Asik G and Kesli Recep. A Diagnostic Algorithm for the Detection of *Clostridium difficile*-Associated Diarrhoea. Balkan Medical Journal. 2016 Feb; 33 (1):80-86. <http://doi:10.5152/balkanmedj.2015.15159>
17. Borren NZ, Ghadermarzi S, Hutfless S and Anantharishnan AN. The emergence of *Clostridium difficile* infection in Asia: A systematic review and meta-analysis of incidence and impact. PLoS ONE 12(5): e0176794. <http://doi.org/10.1371/journal.pone.0176797>
18. Evans CT and Safdar N. Current Trends in Epidemiology and Outcomes of *Clostridium difficile* infection. Clinical Infectious Diseases 2015 May; 15; 60(S2): S66-71. <http://doi:10.1093/cid/civ140>
19. Martin JS, Monaghan TM and Wilcox MH. *Clostridium difficile* infection: advances in epidemiology, diagnosis and transmission. Nature Reviews Gastroenterology and Hepatology. 2016 April; 13(4):206-216. <http://doi:10.1038/nrgastro.2016.25>
20. O'Keefe SJD. Tube feeding, the microbiota, and *Clostridium difficile* infection. World Journal of Gastroenterology. 2010 Jan; 16(2):139-142. <http://doi:10.3748/wjg.v16.i2.139>

21. Imlay H, Kaul D and Rao K. Risk factors for *Clostridium difficile* infection in HIV-infected patients. SAGE Open Medicine. 2016 Dec; (4):1-5.
<http://doi:10.1177/2050312116684295>
22. Longo DL. *Clostridium difficile* Infection. New England Journal of Medicine. 2015 April; 372(16):1539-1548.
23. Alonso CD and Kamboj M. clostridium difficile Infection (CDI) in solid organ and haemopoietic stem cell transplant recipients. Current Infectious Disease. 2014 Aug; 16 (8): 414. <http://doi:10.1007/s11908-014-0414-0>
24. Lees EA, Miyajima F, Pirmohamed M and Carrol ED. The role of *Clostridium difficile* in the paediatric and neonatal gut – a narrative review. European Journal of Clinical Microbiology and Infectious Diseases. 2016 Jul; 35(7):1047-1057.
<http://doi:10.1007/s10096-016-2639-3>
25. Antonara S and Leber AL. Diagnosis of *Clostridium difficile* infection in children. Journal of Clinical Microbiology. 2016 June; 54(6):1425-1433.
<http://doi:10.1128/JCM.03014-15>
26. TECHLAB C. DIFF QUIK CHEK COMPLETE, Alere package insert.
<http://www.techlab.com/wp-content>